Special Issue

Gut Microbiota Metabolites in Intestinal Inflammation and Fibrosis

Message from the Guest Editors

Intestinal microbiota are a dynamic ecosystem, constantly in communication with both the host and the external environment. Among their many benefits to the human organism, such as the development and function of the gastrointestinal tract and intestinal immune system, microbiota also play a crucial role in defense and nutrient supply. These latter two can be accomplished through either microbial antagonism or microbial metabolic activity. Microbial metabolic activity is implicated in a number of processes, such as the fermentation of food carbohydrates, metabolism of xenobiotic substances, production of vitamins, as well as defense against pathogens. Nonetheless, disruption in the composition of the intestinal microbiota leads to a state of dysbiosis, which can also be observed at the metabolic level, and has been associated with various disorders as well as diseases of the digestive tract in addition to other organs and systems of the body.

Guest Editors

Prof. Dr. George Kolios

Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece

Dr. Eirini Filidou

Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece

Deadline for manuscript submissions

closed (25 February 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/166928

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

